Physician profile
Angelo Carpethos
NPI 1518056795
$5,196.43
in general payments reported to CMS, 2019-2025
27 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,171 · 2022: $1,367 · 2023: $933 · 2024: $1,041 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.81 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $831.45 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $630.40 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $573.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $359.36 | 2021-2025 | |
| Amgen INC. | $295.60 | 2021-2024 | Prolia, Evenity |
| Paratek Pharmaceuticals, INC. | $295.04 | 2024-2025 | Nuzyra |
| Biohaven Pharmaceuticals, INC. | $168.87 | 2021 | |
| Novo Nordisk INC | $133.57 | 2022-2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $106.01 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $87.30 | 2022-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $87.12 | 2022 | |
| Lilly USA, LLC | $83.92 | 2021-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $72.81 | 2021 | |
| Genentech USA, INC. | $72.71 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $45.24 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.05 | 2022 | |
| Xeris Pharmaceuticals, INC. | $33.46 | 2021-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $31.97 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $31.17 | 2024-2025 | Zoryve |
| Allergan, INC. | $27.63 | 2022 | |
| Abbott Laboratories | $26.03 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.95 | 2022 | |
| Antares Pharma, INC. | $24.02 | 2022 | |
| Optinose US, INC. | $23.22 | 2022 | |
| Bausch Health US, LLC | $22.84 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Carpethos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.